ライフサイエンスコーパス: tissue inhibitor of metalloproteinase

1 MPs) is relatively unopposed by the specific tissue inhibitors of metalloproteinases.

2 e metalloproteinase interaction sites of the tissue inhibitors of metalloproteinases.

3 alloproteinases in a manner analogous to the tissue inhibitors of metalloproteinases.

4 flections on the evolution of the vertebrate tissue inhibitors of metalloproteinases.

5 f action of the NP mimics that of endogenous tissue inhibitors of metalloproteinases.

6 transforming growth factor beta1 (P=0.0004), tissue inhibitor of metalloproteinase 1 (P=0.0009), gran

7 91(phox(-/-) ) than in WT mice after CCl(4.) Tissue inhibitor of metalloproteinase 1 (TIMP-1) and TIM

8 oteinase 9 (MMP-9) and increased circulating tissue inhibitor of metalloproteinase 1 (TIMP-1) and TIM

9 including COX-2 itself, lipocalin 2 (LCN2), tissue inhibitor of metalloproteinase 1 (TIMP-1), interl

10 e describe a novel approach that would allow tissue inhibitor of metalloproteinase 1 (TIMP-1), the en

11 expression of fibrogenic genes IL-1beta and tissue inhibitor of metalloproteinase 1 (TIMP-1), with t

12 oducts (collagen type 1 alpha 1 (CoL1A1) and tissue inhibitor of metalloproteinase 1 (TIMP1)) were al

13 Herein, we demonstrate that tissue inhibitor of metalloproteinase 1 (TIMP1), a secre

14 8 (IL-8), human beta-defensin 1 (hBD-1), and tissue inhibitor of metalloproteinase 1 and 2 (TIMP-1 an

15 MP-1 was up-regulated, whereas expression of tissue inhibitor of metalloproteinase 1 decreased before

16 factor-beta1, alpha-smooth muscle actin, and tissue inhibitor of metalloproteinase 1 expression and a

17 ries of Dicer(d/d) mice partially normalized tissue inhibitor of metalloproteinase 1 expression and C

18 s after biliary decompression, both MMP3 and tissue inhibitor of metalloproteinase 1 expression decli

19 the eye, and the imbalance between MMP-1 and tissue inhibitor of metalloproteinase 1 may play a role

20 broblasts, reduced hepatic procollagen I and tissue inhibitor of metalloproteinase 1 messenger RNA ex

21 flammation (C-reactive protein, soluble ST2, tissue inhibitor of metalloproteinase 1).

22 , including transforming growth factor beta, tissue inhibitor of metalloproteinase 1, and connective

23 Serum hyaluronic acid, tissue inhibitor of metalloproteinase 1, and procollagen

24 minotransferase, gamma-glutamyl transferase, tissue inhibitor of metalloproteinase 1, C-reactive prot

25 ns of prostaglandin-endoperoxide synthase 2, tissue inhibitor of metalloproteinase 1, Dpp4, nitric ox

26 increased messenger RNA levels of collagen, tissue inhibitor of metalloproteinase 1, matrix metallop

27 ote fibrosis (collagen type I alpha 1 chain, tissue inhibitor of metalloproteinase 1, platelet-derive

28 d in increased expression of MMP3, MMP8, and tissue inhibitor of metalloproteinase 1.

29 the expression of the antiangiogenic factor tissue inhibitor of metalloproteinase 1.

30 Tissue inhibitor of metalloproteinases 1 (TIMP-1) is a m

31 lloproteinase 1 [MMP-1], MMP-13, and MMP-3), tissue inhibitor of metalloproteinases 1 (TIMP-1), and c

32 smosine, matrix metalloproteinase 2 (MMP-2), tissue inhibitor of metalloproteinases 1 (TIMP-1), and T

33 d wine and ethanol upregulated expression of tissue inhibitor of metalloproteinases 1 (TIMP-1), downr

34 invasion assay in the presence or absence of tissue inhibitor of metalloproteinases 1 (TIMP-1), TIMP-

35 r metalloproteinase 2 (MMP-2), MMP-3, MMP-9, tissue inhibitor of metalloproteinases 1 (TIMP-1), TIMP-

36 faip6), matrix metalloproteinase 19 (Mmp19), tissue inhibitor of metalloproteinases 1 (Timp1), and po

37 MMP-9), and the inhibitors of these enzymes (tissue inhibitor of metalloproteinases 1 [TIMP-1] and TI

38 prometastatic matrix metalloproteinase 8 and tissue inhibitor of metalloproteinases 1 in metastatic n

39 DAMTS-5 increased approximately 40-fold, and tissue inhibitor of metalloproteinases 1 increased appro

40 mor necrosis factor receptor 2 or IL-10, and tissue inhibitor of metalloproteinases 1) were identifie

41 P-8 (matrix metalloproteinase-8) and TIMP-1 (tissue inhibitor of metalloproteinases 1); false discove

42 st up-regulated genes (e.g., caspase-3, p21, tissue inhibitor of metalloproteinases 1, 2, and 3, and

43 ulmonary and activation-regulated chemokine, tissue inhibitor of metalloproteinases 1, and soluble CD

44 scores with the lowest levels of IFN-alpha, tissue inhibitor of metalloproteinases 1, and vascular e

45 enic factors (eg, ANG [angiogenin], TIMP1/2 [tissue inhibitor of metalloproteinases 1/2], and RANTES

46 kin 6 [IL-6]; stromal cell-derived factor 1; tissue inhibitor of metalloproteinases 1; and vascular c

47 3 (IL-23), IL-1 receptor I (IL-1RI), IL-17R, tissue inhibitors of metalloproteinase 1 and 2 (TIMP-1 a

48 increased in TAA tissue homogenates, whereas tissue inhibitors of metalloproteinases 1 and 4 decrease

49 se)-3 and MMP-8 synthesis and inducing TIMP (tissue inhibitor of metalloproteinases)-1.

50 03), MMP-2 (p = 0.06), MMP-3 (p = 0.02), and tissue inhibitor of metalloproteinase-1 (p = 0.04) in el

51 TNFalpha, but not IGF-I, induced tissue inhibitor of metalloproteinase-1 (TIMP-1) express

52 Exogenous tissue inhibitor of metalloproteinase-1 (TIMP-1) has a g

53 Tissue inhibitor of metalloproteinase-1 (TIMP-1) is an e

54 Tissue inhibitor of metalloproteinase-1 (TIMP-1) is the

55 lagen I type I, fibronectin, COL1alpha1, and tissue inhibitor of metalloproteinase-1 (TIMP-1) were in

56 treated with IL-1beta express high levels of tissue inhibitor of metalloproteinase-1 (TIMP-1), an imp

57 rix metalloproteinase-2 and 9 (MMP-2 and 9), tissue inhibitor of metalloproteinase-1 (TIMP-1), macrop

58 who underwent routine measurements of plasma tissue inhibitor of metalloproteinase-1 (TIMP-1), metall

59 oteinase-9 (MMP-9) and reduced expression of tissue inhibitor of metalloproteinase-1 (TIMP-1).

60 ted in an increase in expression of the gene tissue inhibitor of metalloproteinase-1 (TIMP-1).

61 smooth muscle actin (alphaSMA), collagen I, tissue inhibitor of metalloproteinase-1 (TIMP1) and tran

62 plored whether OGG1 recruited to intron 1 of tissue inhibitor of metalloproteinase-1 (TIMP1) gene and

63 ed by elevated MMP-1, -2, -3, -7, and -8 and tissue inhibitor of metalloproteinase-1 and -2; and depr

64 -type plasminogen activator while increasing tissue inhibitor of metalloproteinase-1 and plasminogen

65 th a balance between metalloproteinase-8 and tissue inhibitor of metalloproteinase-1 expressions.

66 ase-8 expression and decreased expression of tissue inhibitor of metalloproteinase-1 in pulmonary acu

67 By contrast, levels of mRNA for tissue inhibitor of metalloproteinase-1 in the transfect

68 llagen content and an increase in myocardial tissue inhibitor of metalloproteinase-1 levels.

69 , whereas vascular expression of collagen or tissue inhibitor of metalloproteinase-1 were down-regula

70 owth factor receptor beta, desmin, vimentin, tissue inhibitor of metalloproteinase-1) and fibrosis (r

71 and Lix/CXCL-5), matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1, and apoptosis r

72 s syndrome); and matrix metalloproteinase-3, tissue inhibitor of metalloproteinase-1, and CXCL13 in A

73 Sputum neutrophil elastase, tissue inhibitor of metalloproteinase-1, and TNF-alpha i

74 with gene expression for alpha2(I) collagen, tissue inhibitor of metalloproteinase-1, and transformin

75 n expression of MMP-1, collagen type 1alpha, tissue inhibitor of metalloproteinase-1, and vascular re

76 nogen activator inhibitor (PAI)-1, vimentin, tissue inhibitor of metalloproteinase-1, fibronectin, gr

77 ic responses in HSCs, including secretion of tissue inhibitor of metalloproteinase-1.

78 l mRNA levels of aggrecan, collagen IIa, and tissue inhibitor of metalloproteinase-1.

79 In contrast, the expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) and co

80 The regulation of tissue inhibitor of metalloproteinases-1 (TIMP-1) by UDC

81 Increasing evidence suggests that tissue inhibitor of metalloproteinases-1 (TIMP-1) can di

82 is via its transcriptional regulation of the tissue inhibitor of metalloproteinases-1 (TIMP-1) gene.

83 role in extracellular matrix remodeling, the tissue inhibitor of metalloproteinases-1 (TIMP-1) has be

84 Tissue inhibitor of metalloproteinases-1 (TIMP-1) is a p

85 In astrocytes, the expression of tissue inhibitor of metalloproteinases-1 (TIMP-1) is up-

86 Serum tissue inhibitor of metalloproteinases-1 (TIMP-1) levels

87 Tissue inhibitor of metalloproteinases-1 (TIMP-1) recent

88 ase their proMMP-9 in a unique form, free of tissue inhibitor of metalloproteinases-1 (TIMP-1).

89 nterleukin-6 family, and downstream mediator tissue inhibitor of metalloproteinases-1 (TIMP-1).

90 Tissue inhibitor of metalloproteinases-1 (TIMP1) creates

91 al injury including Cystatin C, Osteopontin, Tissue Inhibitor of Metalloproteinases-1 (TIMP1), beta2-

92 splant [REVERSE]: high osteopontin [OPN] and tissue inhibitor of metalloproteinases-1 [TIMP-1] levels

93 Apolipoprotein E and tissue inhibitor of metalloproteinases-1 knockout mice (

94 protein-10 (IP-10), interleukin (IL)-6, and tissue inhibitor of metalloproteinases-1 on days 8-9 aft

95 to analyze serum levels of hyaluronic acid, tissue inhibitor of metalloproteinases-1, and propeptide

96 the expression of its natural inhibitor, the tissue inhibitor of metalloproteinases-1.

97 metalloproteinase-2, and increased levels of tissue inhibitors of metalloproteinase-1 and -2.

98 The ECM did not affect the secretion of tissue inhibitors of metalloproteinases-1 or -2.

99 aneously increasing tissue inhibitor of MMP (tissue inhibitor of metalloproteinase 2).

100 ating factor, stromal cell-derived factor-1, tissue inhibitor of metalloproteinase 2, and von Willebr

101 rofibrotic (transforming growth factor beta, tissue inhibitor of metalloproteinase 2, collagen type I

102 E cells, without affecting the expression of tissue inhibitor of metalloproteinase 2.

103 Tissue inhibitor of metalloproteinases 2 (TIMP2), a bloo

104 ulinlike growth factor-binding protein 7 and tissue inhibitor of metalloproteinases 2 after surgery (

105 urnover: matrix metalloproteinase 2 (MMP-2), tissue inhibitor of metalloproteinases 2, C-terminal typ

106 tor GM6001 or the specific MT1-MMP inhibitor tissue inhibitor of metalloproteinases 2.

107 ling was associated with decreased levels of tissue inhibitors of metalloproteinase 2, -3, and -4 and

108 nd MMP19, and increased transcript levels of tissue inhibitors of metalloproteinase 2.

109 The endothelial cell (EC)-derived tissue inhibitor of metalloproteinase-2 (TIMP-2) and per

110 nase-2/-9 exhibited little change, the large tissue inhibitor of metalloproteinase-2 (TIMP-2) increas

111 zymography), and cellular contents of MMP2, tissue inhibitor of metalloproteinase-2 (TIMP2), and pho

112 within 12 hours after admission, and urinary tissue inhibitor of metalloproteinase-2 and insulin-like

113 oduct of the G1-cell cycle arrest biomarkers tissue inhibitor of metalloproteinase-2 and insulin-like

114 Performance of the tissue inhibitor of metalloproteinase-2 and insulin-like

115 r operating characteristic curve (95% CI) of tissue inhibitor of metalloproteinase-2 and insulin-like

116 the effect of nonrenal organ dysfunction on tissue inhibitor of metalloproteinase-2 and insulin-like

117 for each patient on enrollment and compared tissue inhibitor of metalloproteinase-2 and insulin-like

118 Urinary tissue inhibitor of metalloproteinase-2 and insulin-like

119 We observed significantly higher urine tissue inhibitor of metalloproteinase-2 and insulin-like

120 In multivariate analysis, the addition of tissue inhibitor of metalloproteinase-2 and insulin-like

121 he performance of the model with and without tissue inhibitor of metalloproteinase-2 and insulin-like

122 nfirmed the involvement of the MT1-MMP/MMP-2/tissue inhibitor of metalloproteinase-2 complex in this

123 We also evaluated MT1-MMP, MMP-2, and tissue inhibitor of metalloproteinase-2 expression in se

124 these, matrix metalloproteinase-2 (MMP2) and tissue inhibitor of metalloproteinase-2 were down-regula

125 Our aim was to evaluate the performance of tissue inhibitor of metalloproteinase-2 x insulin-like g

126 tic performance of renal resistive index and tissue inhibitor of metalloproteinase-2 x insulin-like g

127 The performance of tissue inhibitor of metalloproteinase-2 x insulin-like g

128 Urinary tissue inhibitor of metalloproteinase-2 x insulin-like g

129 The performance of the urinary biomarker, tissue inhibitor of metalloproteinase-2 x insulin-like g

130 Urinary tissue inhibitor of metalloproteinase-2 x insulin-like g

131 oMTb decreased expression of the inhibitors, tissue inhibitor of metalloproteinase-2, -3, and -4.

132 ne domain in the biosensor or treatment with tissue inhibitor of metalloproteinase-2, a cell-impermea

133 a membrane-associated factor, inhibited with tissue inhibitor of metalloproteinase-2, and abolished w

134 content, potentially through an increase in tissue inhibitor of metalloproteinase-2, and transmigrat

135 inhibition of proMMP-2 cleavage; recombinant tissue inhibitor of metalloproteinase-2, which binds to

136 crossed with transgenic mice overexpressing tissue inhibitor of metalloproteinase-2-a natural MMP in

137 alloproteinase-2 and increased expression of tissue inhibitor of metalloproteinase-2.

138 y analysis examined the relationship between tissue inhibitor of metalloproteinases-2 ([TIMP-2]) and

139 Urinary tissue inhibitor of metalloproteinases-2 (TIMP-2) and in

140 Tissue inhibitor of metalloproteinases-2 (TIMP-2) is a b

141 an archetype member of the MMP family, binds tissue inhibitor of metalloproteinases-2 (TIMP-2), activ

142 forming growth factor-beta3 (TGF-beta3), and tissue inhibitor of metalloproteinases-2 (TIMP-2).

143 ne with its physiological protein inhibitor, tissue inhibitor of metalloproteinases-2 (TIMP-2).

144 to patients who exhibit an increased urinary tissue inhibitor of metalloproteinases-2 and insulin-lik

145 In the double MMTV-Wnt1/tissue inhibitor of metalloproteinases-2 transgenic mice

146 ercellular adhesion molecule-1, eotaxin, and tissue inhibitor of metalloproteinases-2.

147 ischemic preconditioning to induce required [tissue inhibitor of metalloproteinases-2]*[insulin-like

148 Absolute changes in [tissue inhibitor of metalloproteinases-2]*[insulin-like

149 e interventional part was change in urinary [tissue inhibitor of metalloproteinases-2]*[insulin-like

150 te ischemic preconditioning could stimulate [tissue inhibitor of metalloproteinases-2]*[insulin-like

151 esponse relationship on absolute changes in [tissue inhibitor of metalloproteinases-2]*[insulin-like

152 mic preconditioning significantly increased [tissue inhibitor of metalloproteinases-2]*[insulin-like

153 ic response in human articular chondrocytes, tissue inhibitor of metalloproteinase 3 (TIMP-3) inducti

154 The tissue inhibitor of metalloproteinase 3 (TIMP-3) is esse

155 Tissue inhibitor of metalloproteinase 3 (TIMP3) and cyto

156 ically, d-flow-induced miR-712 downregulates tissue inhibitor of metalloproteinase 3 (TIMP3) expressi

157 Herein, we show that ITGA7 binds to tissue inhibitor of metalloproteinase 3 (TIMP3) in prost

158 1 (ADAMTS1) and downregulated its inhibitor, tissue inhibitor of metalloproteinase 3 (TIMP3) in respo

159 in natural regulator of TACE activity is the tissue inhibitor of metalloproteinase 3 (Timp3), we hypo

160 e-wide association study; the locus near the tissue inhibitor of metalloproteinase 3 was corroborated

161 TIMP3 (tissue inhibitor of metalloproteinase 3) accumulation in

162 ecanase activity with monoclonal antibodies, tissue inhibitor of metalloproteinases 3 (TIMP-3), and c

163 recognized aggrecanases and their inhibitor, tissue inhibitor of metalloproteinases 3 (TIMP-3), in hu

164 Tissue inhibitor of metalloproteinases 3 (TIMP3) control

165 Tissue inhibitor of metalloproteinases 3 (TIMP3) inhibit

166 We hypothesised that in health, tissue inhibitor of metalloproteinases 3 (TIMP3) modulat

167 We generated oHSVs that express human tissue inhibitor of metalloproteinases 3 (TIMP3) or fire

168 evels of programmed cell death 4 (PDCD4) and tissue inhibitor of metalloproteinases 3 (TIMP3).

169 ents with active AAV, but those of ADAM10 or tissue inhibitor of metalloproteinases 3, which inhibits

170 the endogenous inhibitor of metalloproteases tissue inhibitors of metalloproteinase 3 (TIMP3).

171 usly demonstrated in vitro that a variant of tissue inhibitor of metalloproteinase-3 ([-1A]TIMP3) inh

172 erative disorder, caused by mutations in the Tissue Inhibitor of Metalloproteinase-3 (TIMP3) gene.

173 ogenic effects by upregulating expression of tissue inhibitor of metalloproteinase-3 (TIMP3) in a P53

174 ssion events by delivering molecules such as tissue inhibitor of metalloproteinase-3 and angiopoietin

175 afforded by miR-181b inhibition are largely tissue inhibitor of metalloproteinase-3 dependent, while

176 To investigate whether miR-181b regulates tissue inhibitor of metalloproteinase-3 expression and a

177 hat miR-181b negatively regulates macrophage tissue inhibitor of metalloproteinase-3 expression and v

178 ed expression of predicted miR-181b targets, tissue inhibitor of metalloproteinase-3, and elastin.

179 ed expression of predicted miR-181b targets, tissue inhibitor of metalloproteinase-3, and elastin.

180 l-specific molecule-1, 5'-ecto-nucleotidase, tissue inhibitor of metalloproteinase-3, epidermal growt

181 uble Pref-1A is inhibited by TAPI-0 and by a tissue inhibitor of metalloproteinase-3, TIMP-3, that ca

182 icant reduction of its endogenous inhibitor, tissue inhibitor of metalloproteinase-3.

183 Tissue inhibitor of metalloproteinases-3 (TIMP-3) is a c

184 Tissue inhibitor of metalloproteinases-3 (TIMP-3) is a m

185 Tissue Inhibitor of metalloproteinases-3 (TIMP-3) is a p

186 Tissue inhibitor of metalloproteinases-3 (TIMP-3) plays

187 ddition, CaPPS increased cartilage levels of tissue inhibitor of metalloproteinases-3 (TIMP-3), an en

188 ith pan-metalloproteinase inhibitors or with tissue inhibitors of metalloproteinase-3 reduced neurite

189 yl oxidase, adamalysin metalloproteinase-17, tissue inhibitors of metalloproteinase-3, c-Met and CXCR

190 To quantify the levels of tissue inhibitor of metalloproteinase 4 (TIMP4) and its

191 ls exhibit significantly decreased levels of tissue inhibitor of metalloproteinases 4 (TIMP-4).

192 and alterations in matrix metalloproteinase/tissue inhibitors of metalloproteinase abundance, consis

193 Accurate K(i) values for tissue inhibitors of metalloproteinase and small molecul

194 Tissue inhibitors of metalloproteinases and a specific p

195 jor regulators of MMP-2 activity such as the tissue inhibitors of metalloproteinases and MMP-14.

196 e MMP-9 much less sensitive to inhibition by tissue inhibitors of metalloproteinases and synthetic in

197 cium-binding S100, matrix metalloproteinase, tissue inhibitor of metalloproteinase, and ion channel f

198 ring wing maturation, the Timp gene product, tissue inhibitor of metalloproteinases, and probably oth

199 reduced, pulmonary expression of collagens, tissue inhibitors of metalloproteinases, and fibrogenic

200 hich was caused by the reduced expression of tissue inhibitors of metalloproteinases as well as incre

201 ion of selected matrix metalloproteinases or tissue inhibitors of metalloproteinases between the woun

202 proteins (eg, matrix metalloproteinases and tissue inhibitor of metalloproteinases) compared with wi

203 f invasion-related genes including increased tissue inhibitors of metalloproteinases, decreased metal

204 expression and activity; and (c) stimulated tissue inhibitor of metalloproteinase expression.

205 isintegrin and metalloproteinase domain, and tissue inhibitors of metalloproteinases in M. tuberculos

206 hibition of metalloproteinases in mice using tissue inhibitors of metalloproteinases increases plaque

207 emically characterized MT6-MMP, profiled its tissue inhibitor of metalloproteinase inhibitory spectru

208 reover, small but significant alterations in tissue inhibitors of metalloproteinase levels also occur

209 otoxin variants or suggested by analogy with tissue inhibitors of metalloproteinases, progressively e

210 effects dependent on increased expression of tissue inhibitor of metalloproteinase-sensitive protease

211 inally, studies that either removed or added tissue inhibitor of metalloproteinases species in the my

212 Moreover, heroin-paired cues increased tissue inhibitor of metalloproteinases TIMP-1,2, which c

213 1, matrix metalloproteinase (MMP)-2, MMP-14, tissue inhibitor of metalloproteinase (TIMP) -1, and TIM

214 and activity, concomitant with increases in tissue inhibitor of metalloproteinase (TIMP) 1 and E-cad

215 Conversely, Ad-MMP-2-Si-CM induced tissue inhibitor of metalloproteinase (TIMP) 3 expressio

216 hemokine, and matrix metalloproteinase (MMP)/tissue inhibitor of metalloproteinase (TIMP) expression.

217 BARX2 also increases the expression of the tissue inhibitor of metalloproteinase (TIMP) genes, TIMP

218 ray Human MMP/TIMP Array to quantify MMP and tissue inhibitor of metalloproteinase (TIMP) production

219 between matrix metalloproteinase (MMP)-9 and tissue inhibitor of metalloproteinase (TIMP)-1 and -2 an

220 In contrast, tissue inhibitor of metalloproteinase (TIMP)-1 and -2 se

221 ocyte chemoattractant protein (MCP)-1, IL-8, tissue inhibitor of metalloproteinase (TIMP)-1 and -2, a

222 increased the protein levels of HIF-1alpha, tissue inhibitor of metalloproteinase (TIMP)-1 and colla

223 rs, matrix metalloproteinase (MMP)-8, MMP-9, tissue inhibitor of metalloproteinase (TIMP)-1 and myelo

224 ysis of matrix metalloproteinase (MMP)-8 and tissue inhibitor of metalloproteinase (TIMP)-1 by enzyme

225 Tissue inhibitor of metalloproteinase (TIMP)-1 expressio

226 Low exogenous NO perturbed MMP/tissue inhibitor of metalloproteinase (TIMP)-1 levels by

227 We hypothesized that overexpression of tissue inhibitor of metalloproteinase (TIMP)-1 or TIMP-2

228 COX)-2, matrix metalloproteinase (MMP)-9 and tissue inhibitor of metalloproteinase (TIMP)-1 were obta

229 In addition, during SIBO, MMP-1, tissue inhibitor of metalloproteinase (TIMP)-1, and TIMP

230 e activation states of hepatic MMP-9, MMP-2, tissue inhibitor of metalloproteinase (TIMP)-1, TGF-beta

231 xpression of fibrin, collagen, TGF-beta, and tissue inhibitor of metalloproteinase (TIMP)-2 increased

232 mall interfering RNA suppression of pericyte tissue inhibitor of metalloproteinase (TIMP)-3 (a known

233 ition of TACE activity by specific inhibitor tissue inhibitor of metalloproteinase (TIMP)-3 at dosage

234 Tissue inhibitor of metalloproteinase (Timp)-3 effective

235 s of the matrix metalloproteinase inhibitor, tissue inhibitor of metalloproteinase (TIMP)-4, are asso

236 t growth factor (FGF)-3, its receptor FGFR3, tissue inhibitor of metalloproteinase (TIMP)-4, laminin

237 MP-9 enzyme were critically dependent on the tissue inhibitor of metalloproteinase (TIMP)-free status

238 The tissue inhibitor of metalloproteinase (TIMP)3, a stromal

239 This study investigated the role of tissue inhibitor of metalloproteinases (TIMP) 2 in the c

240 if neutrophil proMMP-9, naturally devoid of tissue inhibitor of metalloproteinases (TIMP), was deliv

241 bit prometastatic matrix metalloproteinases, tissue inhibitor of metalloproteinases (TIMP)-1 has been

242 terleukin 8, hepatocyte growth factor (HGF), tissue inhibitor of metalloproteinases (TIMP)-1, and E-s

243 O), and matrix metalloproteinase (MMP)-2 and tissue inhibitor of metalloproteinases (TIMP)-2 complex.

244 -molecular complex of pro-MMP-2, MMP-14, and tissue inhibitor of metalloproteinases (TIMP)-2.

245 Tissue inhibitor of metalloproteinases (TIMP)-3 is an in

246 Tissue inhibitor of metalloproteinases (TIMP)-3, an endo

247 the endogenous metalloproteinase inhibitor, tissue inhibitor of metalloproteinases (TIMP)-3, through

248 Their main endogenous inhibitor is tissue inhibitor of metalloproteinases (TIMP)-3.

249 utrophil proMMP-9 required activation of the tissue inhibitor of metalloproteinases (TIMP)-free zymog

250 ng to PMN surfaces in a catalytically active tissue inhibitor of metalloproteinases (TIMP)-resistant

251 antitative real-time PCR analysis, levels of tissue inhibitor of metalloproteinases (TIMP-1 and TIMP-

252 , i.e., MMP-9 and MMP-2, and upregulation of tissue inhibitors of metalloproteinase (TIMP) -1 and TIM

253 P. acnes induced the mRNA expression of tissue inhibitors of metalloproteinase (TIMP)-1, the mai

254 including CD34MVD, EMA, p21ras, p21WAF1, and tissue inhibitors of metalloproteinases (TIMP) -2.

255 Previous studies have shown that the tissue inhibitors of metalloproteinases (TIMP)-2 gene, w

256 ilizing a rat model of lung transplantation, tissue inhibitors of metalloproteinases (TIMP-1 and TIMP

257 ted lipocalin, cystatin C, trefoil factor 3, tissue inhibitor of metalloproteinase [TIMP]-1, and beta

258 MMP enzymatic activity is inhibited by the tissue inhibitor of metalloproteinase (TIMP1-4) family o

259 trix metalloproteinases (MMPs 12 and 13) and tissue inhibitor of metalloproteinases (TIMP1), as well

260 talloproteinase MMP2, in the presence of the tissue inhibitor of metalloproteinases TIMP2, constitute

261 ix metalloproteinases (MMPs) 1, 2, 3, and 9; tissue inhibitor of metalloproteinases (TIMPs) 1, 2, and

262 ed MT6-MMPs were found to be associated with tissue inhibitor of metalloproteinases (TIMPs) and did n

263 Tissue inhibitor of metalloproteinases (TIMPs) are the e

264 Tissue inhibitor of metalloproteinases (TIMPs) protect t

265 e expression of their natural inhibitor, the tissue inhibitor of metalloproteinases (TIMPs), are pote

266 , we profiled MMPs and their inhibitors, the tissue inhibitor of metalloproteinases (TIMPs), in sputu

267 pression of MT1-MMP in ECs or by addition of tissue inhibitor of metalloproteinases (TIMPs)-2, -3, an

268 the case of the natural inhibitors of MMPs, tissue inhibitor of metalloproteinases (TIMPs).

269 We have found that LPA downregulates tissue inhibitor of metalloproteinases (TIMPs).

270 derived matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinase (TIMPs) in cancer

271 MMP10, MMP13, and trypsin; inhibition by the tissue inhibitors of metalloproteinases (TIMPs) 1 and 2;

272 x metalloproteinases (MMPs) 1, 3, and 13 and tissue inhibitors of metalloproteinases (TIMPs) 1 and 3

273 Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) are invo

274 Tissue inhibitors of metalloproteinases (TIMPs) are natu

275 Tissue inhibitors of metalloproteinases (TIMPs) are plei

276 The four tissue inhibitors of metalloproteinases (TIMPs) are pote

277 sion of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) during t

278 The tissue inhibitors of metalloproteinases (TIMPs) function

279 The balance of MMPs and tissue inhibitors of metalloproteinases (TIMPs) governs

280 pecific matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in the a

281 Tissue inhibitors of metalloproteinases (TIMPs) inhibit

282 Tissue inhibitors of metalloproteinases (TIMPs) inhibit

283 etalloproteinases (MMPs) and the activity of tissue inhibitors of metalloproteinases (TIMPs) is impli

284 vels of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) of HGFs

285 Four tissue inhibitors of metalloproteinases (TIMPs) regulate

286 The avid binding of tissue inhibitors of metalloproteinases (TIMPs) to matri

287 alloproteinases (Mmps) regulated by secreted tissue inhibitors of metalloproteinases (Timps), cleave

288 proteinases (MMPs) and their inhibitors, the tissue inhibitors of metalloproteinases (TIMPs), in the

289 and binding to their endogenous inhibitors, tissue inhibitors of metalloproteinases (TIMPs), is abno

290 between matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs), leading

291 Jawed vertebrates (Gnathostomes) have 4 tissue inhibitors of metalloproteinases (TIMPs), multifu

292 Tissue inhibitors of metalloproteinases (TIMPs), the end

293 To understand the regulation of MMP-10 by tissue inhibitors of metalloproteinases (TIMPs), we have

294 ted by their endogenous inhibitors, known as tissue inhibitors of metalloproteinases (TIMPs).

295 GFs) and the expression of selected MMPs and tissue inhibitors of metalloproteinases (TIMPs).

296 at are regulated, in part, by the endogenous tissue inhibitors of metalloproteinases (TIMPs).

297 inases (MMPs) and their specific inhibitors, tissue inhibitors of metalloproteinases (TIMPs).

298 eem to have a major role in the secretion of tissue inhibitors of metalloproteinases (TIMPs).

299 s may be an effective method for discovering tissue inhibitor of metalloproteinase variants that disc

300 nes involved in tumor cell migration such as tissue inhibitors of metalloproteinases, were also incre